The MILESTONE study, sponsored by Zhongda Hospital, aims to evaluate the efficacy of multi-electrode catheter-based endovascular denervation in improving glucose metabolism and insulin sensitivity in patients with Type 2 Diabetes Mellitus (T2DM). Given the increasing prevalence of T2DM globally, successful outcomes from this trial could position the intervention as a novel therapeutic option in a market characterized by a high demand for effective diabetes management solutions. The competitive landscape includes traditional pharmacological treatments and emerging technologies targeting metabolic pathways. Diligence should focus on the trial's recruitment progress, safety profile, and potential regulatory pathways, especially considering the device nature of the intervention.